Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 1043 entries
Sorted by: Best Match Show Resources per page
Targeting hyaluronan for the treatment of pancreatic ductal adenocarcinoma.

Acta pharmaceutica Sinica. B

Sato N, Cheng XB, Kohi S, Koga A, Hirata K.
PMID: 27006892
Acta Pharm Sin B. 2016 Mar;6(2):101-5. doi: 10.1016/j.apsb.2016.01.002. Epub 2016 Jan 21.

Progression of cancer is often associated with interactions between cancer cells and extracellular matrix (ECM) surrounding them. Increasing evidence has suggested that accumulation of hyaluronan (HA), a major component of ECM, provides a favorable microenvironment for cancer progression. Pancreatic...

Cite
Sato N, Cheng XB, Kohi S, et al. Targeting hyaluronan for the treatment of pancreatic ductal adenocarcinoma. Acta Pharm Sin B. 2016;6(2):101-5doi: 10.1016/j.apsb.2016.01.002.
Sato, N., Cheng, X. B., Kohi, S., Koga, A., & Hirata, K. (2016). Targeting hyaluronan for the treatment of pancreatic ductal adenocarcinoma. Acta pharmaceutica Sinica. B, 6(2), 101-5. https://doi.org/10.1016/j.apsb.2016.01.002
Sato, Norihiro, et al. "Targeting hyaluronan for the treatment of pancreatic ductal adenocarcinoma." Acta pharmaceutica Sinica. B vol. 6,2 (2016): 101-5. doi: https://doi.org/10.1016/j.apsb.2016.01.002
Sato N, Cheng XB, Kohi S, Koga A, Hirata K. Targeting hyaluronan for the treatment of pancreatic ductal adenocarcinoma. Acta Pharm Sin B. 2016 Mar;6(2):101-5. doi: 10.1016/j.apsb.2016.01.002. Epub 2016 Jan 21. PMID: 27006892; PMCID: PMC4788704.
Copy Download .nbib Format: NLM
Establishment and characterization of arsenic trioxide resistant KB/ATO cells.

Acta pharmaceutica Sinica. B

Zhang YK, Dai C, Yuan CG, Wu HC, Xiao Z, Lei ZN, Yang DH, Le XC, Fu L, Chen ZS.
PMID: 28924550
Acta Pharm Sin B. 2017 Sep;7(5):564-570. doi: 10.1016/j.apsb.2017.04.001. Epub 2017 Apr 28.

Arsenic trioxide (ATO) is used as a chemotherapeutic agent for the treatment of acute promyelocytic leukemia. However, increasing drug resistance is reducing its efficacy. Therefore, a better understanding of ATO resistance mechanism is required. In this study, we established...

Cite
Zhang YK, Dai C, Yuan CG, et al. Establishment and characterization of arsenic trioxide resistant KB/ATO cells. Acta Pharm Sin B. 2017;7(5):564-570doi: 10.1016/j.apsb.2017.04.001.
Zhang, Y. K., Dai, C., Yuan, C. G., Wu, H. C., Xiao, Z., Lei, Z. N., Yang, D. H., Le, X. C., Fu, L., & Chen, Z. S. (2017). Establishment and characterization of arsenic trioxide resistant KB/ATO cells. Acta pharmaceutica Sinica. B, 7(5), 564-570. https://doi.org/10.1016/j.apsb.2017.04.001
Zhang, Yun-Kai, et al. "Establishment and characterization of arsenic trioxide resistant KB/ATO cells." Acta pharmaceutica Sinica. B vol. 7,5 (2017): 564-570. doi: https://doi.org/10.1016/j.apsb.2017.04.001
Zhang YK, Dai C, Yuan CG, Wu HC, Xiao Z, Lei ZN, Yang DH, Le XC, Fu L, Chen ZS. Establishment and characterization of arsenic trioxide resistant KB/ATO cells. Acta Pharm Sin B. 2017 Sep;7(5):564-570. doi: 10.1016/j.apsb.2017.04.001. Epub 2017 Apr 28. PMID: 28924550; PMCID: PMC5595296.
Copy Download .nbib Format: NLM
Intracellular pharmacokinetic study of zidovudine and its phosphorylated metabolites.

Acta pharmaceutica Sinica. B

Mu L, Zhou R, Tang F, Liu X, Li S, Xie F, Xie X, Peng J, Yu P.
PMID: 27006900
Acta Pharm Sin B. 2016 Mar;6(2):158-62. doi: 10.1016/j.apsb.2015.10.002. Epub 2015 Dec 21.

Zidovudine (AZT), the first drug approved by the US Food and Drug Administration for the treatment of human immunodeficiency virus (HIV) infection, is metabolized in the host cells to 5'-AZT triphosphate (AZT-TP) which inhibits HIV reverse transcriptase. As the...

Cite
Mu L, Zhou R, Tang F, et al. Intracellular pharmacokinetic study of zidovudine and its phosphorylated metabolites. Acta Pharm Sin B. 2015;6(2):158-62doi: 10.1016/j.apsb.2015.10.002.
Mu, L., Zhou, R., Tang, F., Liu, X., Li, S., Xie, F., Xie, X., Peng, J., & Yu, P. (2016). Intracellular pharmacokinetic study of zidovudine and its phosphorylated metabolites. Acta pharmaceutica Sinica. B, 6(2), 158-62. https://doi.org/10.1016/j.apsb.2015.10.002
Mu, Lingli, et al. "Intracellular pharmacokinetic study of zidovudine and its phosphorylated metabolites." Acta pharmaceutica Sinica. B vol. 6,2 (2016): 158-62. doi: https://doi.org/10.1016/j.apsb.2015.10.002
Mu L, Zhou R, Tang F, Liu X, Li S, Xie F, Xie X, Peng J, Yu P. Intracellular pharmacokinetic study of zidovudine and its phosphorylated metabolites. Acta Pharm Sin B. 2016 Mar;6(2):158-62. doi: 10.1016/j.apsb.2015.10.002. Epub 2015 Dec 21. PMID: 27006900; PMCID: PMC4788712.
Copy Download .nbib Format: NLM
Comparison of drug release from liquid crystalline monoolein dispersions and solid lipid nanoparticles using a flow cytometric technique.

Acta pharmaceutica Sinica. B

Dawoud MZ, Nasr M.
PMID: 27006901
Acta Pharm Sin B. 2016 Mar;6(2):163-9. doi: 10.1016/j.apsb.2016.01.004. Epub 2016 Jan 25.

Colloidal lipid particles such as solid lipid nanoparticles and liquid crystalline nanoparticles have great opportunities as drug carriers especially for lipophilic drugs intended for intravenous administration. In order to evaluate drug release from these nanoparticles and determine their behavior...

Cite
Dawoud MZ, Nasr M. Comparison of drug release from liquid crystalline monoolein dispersions and solid lipid nanoparticles using a flow cytometric technique. Acta Pharm Sin B. 2016;6(2):163-9doi: 10.1016/j.apsb.2016.01.004.
Dawoud, M. Z., & Nasr, M. (2016). Comparison of drug release from liquid crystalline monoolein dispersions and solid lipid nanoparticles using a flow cytometric technique. Acta pharmaceutica Sinica. B, 6(2), 163-9. https://doi.org/10.1016/j.apsb.2016.01.004
Dawoud, Mohamed Z, and Nasr, Mohamed. "Comparison of drug release from liquid crystalline monoolein dispersions and solid lipid nanoparticles using a flow cytometric technique." Acta pharmaceutica Sinica. B vol. 6,2 (2016): 163-9. doi: https://doi.org/10.1016/j.apsb.2016.01.004
Dawoud MZ, Nasr M. Comparison of drug release from liquid crystalline monoolein dispersions and solid lipid nanoparticles using a flow cytometric technique. Acta Pharm Sin B. 2016 Mar;6(2):163-9. doi: 10.1016/j.apsb.2016.01.004. Epub 2016 Jan 25. PMID: 27006901; PMCID: PMC4788703.
Copy Download .nbib Format: NLM
An Odyssey in antiviral drug development-50 years at the Rega Institute: 1964-2014.

Acta pharmaceutica Sinica. B

De Clercq E.
PMID: 26713268
Acta Pharm Sin B. 2015 Nov;5(6):520-43. doi: 10.1016/j.apsb.2015.09.001. Epub 2015 Nov 02.

No abstract available.

Cite
De Clercq E. An Odyssey in antiviral drug development-50 years at the Rega Institute: 1964-2014. Acta Pharm Sin B. 2015;5(6):520-43doi: 10.1016/j.apsb.2015.09.001.
De Clercq, E. (2015). An Odyssey in antiviral drug development-50 years at the Rega Institute: 1964-2014. Acta pharmaceutica Sinica. B, 5(6), 520-43. https://doi.org/10.1016/j.apsb.2015.09.001
De Clercq, Erik. "An Odyssey in antiviral drug development-50 years at the Rega Institute: 1964-2014." Acta pharmaceutica Sinica. B vol. 5,6 (2015): 520-43. doi: https://doi.org/10.1016/j.apsb.2015.09.001
De Clercq E. An Odyssey in antiviral drug development-50 years at the Rega Institute: 1964-2014. Acta Pharm Sin B. 2015 Nov;5(6):520-43. doi: 10.1016/j.apsb.2015.09.001. Epub 2015 Nov 02. PMID: 26713268; PMCID: PMC4675811.
Copy Download .nbib Format: NLM
Fucoidan protects hepatocytes from apoptosis and inhibits invasion of hepatocellular carcinoma by up-regulating p42/44 MAPK-dependent NDRG-1/CAP43.

Acta pharmaceutica Sinica. B

Cho Y, Yoon JH, Yoo JJ, Lee M, Lee DH, Cho EJ, Lee JH, Yu SJ, Kim YJ, Kim CY.
PMID: 26713269
Acta Pharm Sin B. 2015 Nov;5(6):544-53. doi: 10.1016/j.apsb.2015.09.004. Epub 2015 Nov 18.

Fucoidan is a traditional Chinese medicine suggested to possess anti-tumor effects. In this study the anti-metastatic effects of fucoidan were investigated in vitro in human hepatocellular carcinoma (HCC) cells (Huh-7 and SNU-761) under normoxic and hypoxic conditions and in...

Cite
Cho Y, Yoon JH, Yoo JJ, et al. Fucoidan protects hepatocytes from apoptosis and inhibits invasion of hepatocellular carcinoma by up-regulating p42/44 MAPK-dependent NDRG-1/CAP43. Acta Pharm Sin B. 2015;5(6):544-53doi: 10.1016/j.apsb.2015.09.004.
Cho, Y., Yoon, J. H., Yoo, J. J., Lee, M., Lee, D. H., Cho, E. J., Lee, J. H., Yu, S. J., Kim, Y. J., & Kim, C. Y. (2015). Fucoidan protects hepatocytes from apoptosis and inhibits invasion of hepatocellular carcinoma by up-regulating p42/44 MAPK-dependent NDRG-1/CAP43. Acta pharmaceutica Sinica. B, 5(6), 544-53. https://doi.org/10.1016/j.apsb.2015.09.004
Cho, Yuri, et al. "Fucoidan protects hepatocytes from apoptosis and inhibits invasion of hepatocellular carcinoma by up-regulating p42/44 MAPK-dependent NDRG-1/CAP43." Acta pharmaceutica Sinica. B vol. 5,6 (2015): 544-53. doi: https://doi.org/10.1016/j.apsb.2015.09.004
Cho Y, Yoon JH, Yoo JJ, Lee M, Lee DH, Cho EJ, Lee JH, Yu SJ, Kim YJ, Kim CY. Fucoidan protects hepatocytes from apoptosis and inhibits invasion of hepatocellular carcinoma by up-regulating p42/44 MAPK-dependent NDRG-1/CAP43. Acta Pharm Sin B. 2015 Nov;5(6):544-53. doi: 10.1016/j.apsb.2015.09.004. Epub 2015 Nov 18. PMID: 26713269; PMCID: PMC4675821.
Copy Download .nbib Format: NLM
The antitumor effect of tanshinone IIA on anti-proliferation and decreasing VEGF/VEGFR2 expression on the human non-small cell lung cancer A549 cell line.

Acta pharmaceutica Sinica. B

Xie J, Liu J, Liu H, Liang S, Lin M, Gu Y, Liu T, Wang D, Ge H, Mo SL.
PMID: 26713270
Acta Pharm Sin B. 2015 Nov;5(6):554-63. doi: 10.1016/j.apsb.2015.07.008. Epub 2015 Sep 26.

The effects of tanshinone IIA on the proliferation of the human non-small cell lung cancer cell line A549 and its possible mechanism on the VEGF/VEGFR signal pathway were investigated. The exploration of the interaction between tanshinone IIA and its...

Cite
Xie J, Liu J, Liu H, et al. The antitumor effect of tanshinone IIA on anti-proliferation and decreasing VEGF/VEGFR2 expression on the human non-small cell lung cancer A549 cell line. Acta Pharm Sin B. 2015;5(6):554-63doi: 10.1016/j.apsb.2015.07.008.
Xie, J., Liu, J., Liu, H., Liang, S., Lin, M., Gu, Y., Liu, T., Wang, D., Ge, H., & Mo, S. L. (2015). The antitumor effect of tanshinone IIA on anti-proliferation and decreasing VEGF/VEGFR2 expression on the human non-small cell lung cancer A549 cell line. Acta pharmaceutica Sinica. B, 5(6), 554-63. https://doi.org/10.1016/j.apsb.2015.07.008
Xie, Jun, et al. "The antitumor effect of tanshinone IIA on anti-proliferation and decreasing VEGF/VEGFR2 expression on the human non-small cell lung cancer A549 cell line." Acta pharmaceutica Sinica. B vol. 5,6 (2015): 554-63. doi: https://doi.org/10.1016/j.apsb.2015.07.008
Xie J, Liu J, Liu H, Liang S, Lin M, Gu Y, Liu T, Wang D, Ge H, Mo SL. The antitumor effect of tanshinone IIA on anti-proliferation and decreasing VEGF/VEGFR2 expression on the human non-small cell lung cancer A549 cell line. Acta Pharm Sin B. 2015 Nov;5(6):554-63. doi: 10.1016/j.apsb.2015.07.008. Epub 2015 Sep 26. PMID: 26713270; PMCID: PMC4675810.
Copy Download .nbib Format: NLM
Cysteine proteases as therapeutic targets: does selectivity matter? A systematic review of calpain and cathepsin inhibitors.

Acta pharmaceutica Sinica. B

Siklos M, BenAissa M, Thatcher GR.
PMID: 26713267
Acta Pharm Sin B. 2015 Nov;5(6):506-19. doi: 10.1016/j.apsb.2015.08.001. Epub 2015 Sep 26.

Cysteine proteases continue to provide validated targets for treatment of human diseases. In neurodegenerative disorders, multiple cysteine proteases provide targets for enzyme inhibitors, notably caspases, calpains, and cathepsins. The reactive, active-site cysteine provides specificity for many inhibitor designs over...

Cite
Siklos M, BenAissa M, Thatcher GR. Cysteine proteases as therapeutic targets: does selectivity matter? A systematic review of calpain and cathepsin inhibitors. Acta Pharm Sin B. 2015;5(6):506-19doi: 10.1016/j.apsb.2015.08.001.
Siklos, M., BenAissa, M., & Thatcher, G. R. (2015). Cysteine proteases as therapeutic targets: does selectivity matter? A systematic review of calpain and cathepsin inhibitors. Acta pharmaceutica Sinica. B, 5(6), 506-19. https://doi.org/10.1016/j.apsb.2015.08.001
Siklos, Marton, et al. "Cysteine proteases as therapeutic targets: does selectivity matter? A systematic review of calpain and cathepsin inhibitors." Acta pharmaceutica Sinica. B vol. 5,6 (2015): 506-19. doi: https://doi.org/10.1016/j.apsb.2015.08.001
Siklos M, BenAissa M, Thatcher GR. Cysteine proteases as therapeutic targets: does selectivity matter? A systematic review of calpain and cathepsin inhibitors. Acta Pharm Sin B. 2015 Nov;5(6):506-19. doi: 10.1016/j.apsb.2015.08.001. Epub 2015 Sep 26. PMID: 26713267; PMCID: PMC4675809.
Copy Download .nbib Format: NLM
Four new phenolic glycosides from Baoyuan decoction.

Acta pharmaceutica Sinica. B

Ma X, Guo X, Zhao M, Tu P, Jiang Y.
PMID: 28303223
Acta Pharm Sin B. 2017 Mar;7(2):173-178. doi: 10.1016/j.apsb.2016.08.004. Epub 2016 Sep 16.

Four new phenolic glycosides, including two flavonoid glycosides (

Cite
Ma X, Guo X, Zhao M, et al. Four new phenolic glycosides from Baoyuan decoction. Acta Pharm Sin B. 2016;7(2):173-178doi: 10.1016/j.apsb.2016.08.004.
Ma, X., Guo, X., Zhao, M., Tu, P., & Jiang, Y. (2017). Four new phenolic glycosides from Baoyuan decoction. Acta pharmaceutica Sinica. B, 7(2), 173-178. https://doi.org/10.1016/j.apsb.2016.08.004
Ma, Xiaoli, et al. "Four new phenolic glycosides from Baoyuan decoction." Acta pharmaceutica Sinica. B vol. 7,2 (2017): 173-178. doi: https://doi.org/10.1016/j.apsb.2016.08.004
Ma X, Guo X, Zhao M, Tu P, Jiang Y. Four new phenolic glycosides from Baoyuan decoction. Acta Pharm Sin B. 2017 Mar;7(2):173-178. doi: 10.1016/j.apsb.2016.08.004. Epub 2016 Sep 16. PMID: 28303223; PMCID: PMC5343191.
Copy Download .nbib Format: NLM
Salvianolic acid A alleviates renal injury in systemic lupus erythematosus induced by pristane in BALB/c mice.

Acta pharmaceutica Sinica. B

Lin Y, Yan Y, Zhang H, Chen Y, He Y, Wang S, Fang L, Lv Y, Du G.
PMID: 28303221
Acta Pharm Sin B. 2017 Mar;7(2):159-166. doi: 10.1016/j.apsb.2016.07.001. Epub 2016 Oct 21.

The purpose of this study was to investigate the effects of salvianolic acid A (SAA) in systemic lupus erythematosus (SLE) induced by pristane in BALB/c mice. Lupus mice were established by confirming elevated levels of autoantibodies and IL-6 after...

Cite
Lin Y, Yan Y, Zhang H, et al. Salvianolic acid A alleviates renal injury in systemic lupus erythematosus induced by pristane in BALB/c mice. Acta Pharm Sin B. 2016;7(2):159-166doi: 10.1016/j.apsb.2016.07.001.
Lin, Y., Yan, Y., Zhang, H., Chen, Y., He, Y., Wang, S., Fang, L., Lv, Y., & Du, G. (2017). Salvianolic acid A alleviates renal injury in systemic lupus erythematosus induced by pristane in BALB/c mice. Acta pharmaceutica Sinica. B, 7(2), 159-166. https://doi.org/10.1016/j.apsb.2016.07.001
Lin, Yihuang, et al. "Salvianolic acid A alleviates renal injury in systemic lupus erythematosus induced by pristane in BALB/c mice." Acta pharmaceutica Sinica. B vol. 7,2 (2017): 159-166. doi: https://doi.org/10.1016/j.apsb.2016.07.001
Lin Y, Yan Y, Zhang H, Chen Y, He Y, Wang S, Fang L, Lv Y, Du G. Salvianolic acid A alleviates renal injury in systemic lupus erythematosus induced by pristane in BALB/c mice. Acta Pharm Sin B. 2017 Mar;7(2):159-166. doi: 10.1016/j.apsb.2016.07.001. Epub 2016 Oct 21. PMID: 28303221; PMCID: PMC5343112.
Copy Download .nbib Format: NLM
Simultaneous determination of 14 active constituents of Shengjiang Xiexin decoction using ultrafast liquid chromatography coupled with electrospray ionization tandem mass spectrometry.

Acta pharmaceutica Sinica. B

Peng G, Guan H, Wang X, Shi Y.
PMID: 28303226
Acta Pharm Sin B. 2017 Mar;7(2):193-201. doi: 10.1016/j.apsb.2016.11.006. Epub 2016 Dec 30.

An effective herbal medicinal prescription of Shengjiang Xiexin decoction (SXD) was used in treating the inflammatory bowel disease in clinic. In this study, an ultrafast liquid chromatography-tandem mass spectrometry (UFLC-MS/MS) method was developed to separate and to simultaneously determine...

Cite
Peng G, Guan H, Wang X, et al. Simultaneous determination of 14 active constituents of Shengjiang Xiexin decoction using ultrafast liquid chromatography coupled with electrospray ionization tandem mass spectrometry. Acta Pharm Sin B. 2016;7(2):193-201doi: 10.1016/j.apsb.2016.11.006.
Peng, G., Guan, H., Wang, X., & Shi, Y. (2017). Simultaneous determination of 14 active constituents of Shengjiang Xiexin decoction using ultrafast liquid chromatography coupled with electrospray ionization tandem mass spectrometry. Acta pharmaceutica Sinica. B, 7(2), 193-201. https://doi.org/10.1016/j.apsb.2016.11.006
Peng, Gang, et al. "Simultaneous determination of 14 active constituents of Shengjiang Xiexin decoction using ultrafast liquid chromatography coupled with electrospray ionization tandem mass spectrometry." Acta pharmaceutica Sinica. B vol. 7,2 (2017): 193-201. doi: https://doi.org/10.1016/j.apsb.2016.11.006
Peng G, Guan H, Wang X, Shi Y. Simultaneous determination of 14 active constituents of Shengjiang Xiexin decoction using ultrafast liquid chromatography coupled with electrospray ionization tandem mass spectrometry. Acta Pharm Sin B. 2017 Mar;7(2):193-201. doi: 10.1016/j.apsb.2016.11.006. Epub 2016 Dec 30. PMID: 28303226; PMCID: PMC5343114.
Copy Download .nbib Format: NLM
Development and validation of an HPLC-MS/MS method to determine clopidogrel in human plasma.

Acta pharmaceutica Sinica. B

Liu G, Dong C, Shen W, Lu X, Zhang M, Gui Y, Zhou Q, Yu C.
PMID: 26904399
Acta Pharm Sin B. 2016 Jan;6(1):55-63. doi: 10.1016/j.apsb.2015.11.001. Epub 2015 Dec 15.

A quantitative method for clopidogrel using online-SPE tandem LC-MS/MS was developed and fully validated according to the well-established FDA guidelines. The method achieves adequate sensitivity for pharmacokinetic studies, with lower limit of quantifications (LLOQs) as low as 10 pg/mL....

Cite
Liu G, Dong C, Shen W, et al. Development and validation of an HPLC-MS/MS method to determine clopidogrel in human plasma. Acta Pharm Sin B. 2015;6(1):55-63doi: 10.1016/j.apsb.2015.11.001.
Liu, G., Dong, C., Shen, W., Lu, X., Zhang, M., Gui, Y., Zhou, Q., & Yu, C. (2016). Development and validation of an HPLC-MS/MS method to determine clopidogrel in human plasma. Acta pharmaceutica Sinica. B, 6(1), 55-63. https://doi.org/10.1016/j.apsb.2015.11.001
Liu, Gangyi, et al. "Development and validation of an HPLC-MS/MS method to determine clopidogrel in human plasma." Acta pharmaceutica Sinica. B vol. 6,1 (2016): 55-63. doi: https://doi.org/10.1016/j.apsb.2015.11.001
Liu G, Dong C, Shen W, Lu X, Zhang M, Gui Y, Zhou Q, Yu C. Development and validation of an HPLC-MS/MS method to determine clopidogrel in human plasma. Acta Pharm Sin B. 2016 Jan;6(1):55-63. doi: 10.1016/j.apsb.2015.11.001. Epub 2015 Dec 15. PMID: 26904399; PMCID: PMC4724691.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 1043 entries